Abstract:Glioblastoma is a most aggressive brain tumor with a median overall survival of less than two years. The current treatment is surgery, chemotherapy, and radiotherapy. However, glioblastoma is difficult to treat and recurs some time after treatment. Several reports have shown that intratumoral heterogeneity is a hallmark of glioblastoma, and it is often said to be a factor that contributes to tumor progression and tumor relapse. Based on the single-cell gene expression profiling, glioblastoma is found to be composed of tumor cells with three different subtype signatures namely proneural, classical, and mesenchymal. These subtypes may transition between each other, which may be affected, and/or potentially controlled, by genetic and epigenetic modifications. Even microenvironmental events and communication between different subtype cells within the same tumor may play a role. Studies in this thesis focused on identifying regulators of subtype transitions and their involvement in cell-to-cell communication in individual glioblastomas. Study I used several analytical approaches including connectivity map analysis, overexpression screen, RNA-sequencing, and gene expression profiling. SOX2 was identified to have the capacity to transition mesenchymal gene expression subtype glioblastoma cells back to a non-mesenchymal signature. Subsequently, SFRP2 was identified as a SOX2 antagonist able to induce a mesenchymal transition. In line with this, SFRP2 was found expressed at a higher level in mesenchymal as compared to proneural and classical TCGA glioblastoma samples. In vitro, SFRP2 decreased tumor sphere formation and cell proliferation, and increased cell invasion capacity and sensitivity towards apoptotic stimuli. Spatial gene expression analysis found SFRP2correlated genes to be expressed in a higher level in vascularized areas in glioblastoma, as opposed to SOX2-correlated genes that were highly expressed in cellular tumor regions. Moreover, conditioned media from SFRP2 transitioned cells induced more MRC1 (encodes CD206) expression in human monocytes in vitro. Collectively, these experiments identified SFPR2 as a SOX2 antagonist and inducer of mesenchymal transition in glioblastoma. In Study II PROX1 was found expressed at a lower level in glioblastoma as compared to lowgrade gliomas. Tumors with lower PROX1 correlated with a mesenchymal subtype and patients exhibited shorter survival. Suppression of PROX1 in glioblastoma cell lines with high PROX1 levels induced transition to a mesenchymal glioblastoma subtype signature. Conversely, overexpression of PROX1 transitioned cells to a non-mesenchymal subtype signature. In co-occurrence with these transitions, PROX1 functionally impacted on cell proliferation and levels of several cell cycle proteins. SOX2 was identified as an upstream signaling component of PROX1, and thus SOX2 and PROX1 levels decreased upon treatment with a CDK inhibitor. By co-immunoprecipitation experiments PROX1 was found to interact with THRAP3 in the nucleus. Depletion of THRAP3 increased PROX1 expression and protein stability. Based on previous reports on THRAP3, these findings suggest THRAP3 to be involved in the transcriptional regulation of PROX1. These results underscore a functional role of PROX1 in glioblastoma development and with implications for survival outcome. In study III the well-known U-343 cell line system was used as a model system to study intratumoral heterogeneity and cell-to-cell communication. The four cell lines U-343 MG, U343 MGa, U-343 MGa 31L and U-343 MGa Cl2:6 are derived from the same glioblastoma, and display different phenotypes including marker expression, cells shape, and proliferation. Gene expression and DNA copy number analyses suggested their shared derivations from a common ancestor in a tumor evolutionary relationship. Temozolomide (TMZ) sensitivity of the individual cell lines was determined. In a cell culture composed of a mixture of all four cell lines, the one with the lowest sensitivity outlived the others during TMZ treatment, which modeled the appearance of drug resistance. Finally, co-culture and conditioned media experiments revealed complex interactions between the U-343 cell lines through signaling by cell-to-cell contact or secreted proteins. These findings provide a model for research on intratumoral heterogeneity, both with regard to appearance of drug resistance and to interclonal interactions. Collectively, these studies provide insights into the complexity of intratumoral heterogeneity, including subtype transitions during tumor progression and interclonal communication. Intratumoral heterogeneity is thus important to consider when designing new therapeutic strategies and may also in itself pose novel therapeutic targets.

Path-21. Singel Cell Transcriptomics Of Spinal Ependymoma Subtypes Identifies Intratumoral Heterogeneity

Epco-60. Expression Of Early Progenitor Markers Within Nf2-Associated Spinal Ependymoma

Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation

Stem-11. Multidimensional Profiling Of Tumor Cell Heterogeneity Reveals Cell-Lineage Specific Functions In Supratentorial Ependymomas

Spatial Transcriptomics of Spinal Ependymoma in NF2-related Schwannomatosis

Epco-30. Transcriptomic Analysis Identifies Regional Biology And Outcome Heterogeneity In Medulloblastoma And Ependymoma Subtypes

Abstract PO-016: Revealing the cellular ecosystem and signaling pathways of posterior fossa childhood ependymoma with single-cell transcriptomic profiling

Epco-54. Multiomic Analysis Of Spinal Ependymomas Reveals Mechanisms Of Tumor Aggressiveness With Mycn Amplification

Single-Cell RNA Sequencing Unravels Upregulation of Immune Cell Crosstalk in Relapsed Pediatric Ependymoma

Transcriptomic landscape identifies two unrecognized ependymoma subtypes and novel pathways in medulloblastoma

Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas

Epco-40. Transcriptional Trajectory Inference Of Image-Localized, Multi-Regional High-Grade Glioma Biopsies Reveals Distinct Population Ecologies And Sex-Associated Enriched Pathways

Path-17. Molecular Classification Of H3K27-Wildtype Spinal Cord Gliomas: Implications For Prognosis And Therapeutics

EPEN-07. SINGLE-CELL RNA SEQUENCING IDENTIFIES A UNIQUE MYELOID SUBPOPULATION ASSOCIATED WITH MESENCHYMAL TUMOR SUBPOPULATION IN POOR OUTCOME PEDIATRIC EPENDYMOMA

HGG-18. SINGLE CELL RNA-SEQ ANALYSIS OF PEDIATRIC HIGH-GRADE GLIOMA PATIENT SAMPLES IDENTIFIES COMMON GLIAL AND IMMUNE CELL TYPES THAT HELP TO EXPLAIN HETEROGENEITY AND TUMORIGENESIS

Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology

Profiling spatiotemporal gene expression of the developing human spinal cord and implications for ependymoma origin

Epco-42. Single-Cell Multiomic Analysis Of Brain Metastases Across Multiple Primary Tumor Types

Single-cell RNA sequencing highlights intratumor heterogeneity and intercellular network featured in adamantinomatous craniopharyngioma

Intratumoral heterogeneity in glioblastoma: subtype transition and cell-to-cell communication

Epco-48. Resolving Intratumoral Transcriptional Heterogeneity Across The Core-Edge Spatial Axis In Glioblastoma